Literature DB >> 36050978

The importance of randomization in clinical research.

Varun Sundaram1,2,3, Padmini Selvaganesan1,3, Salil Deo1,3, Mohamad Karnib1,2,3.   

Abstract

Studies evaluating average treatment effects (ATE) of an intervention could broadly be classified into those with observational and randomized designs. Observational studies are limited by confounding, in addition to selection and information bias, making the evaluation of ATE hypothesis generating and not hypothesis testing. Randomization attempts to reduce the systemic error introduced by observational studies by ensuring equal distribution of prognostic factors between the treatment and control groups, thereby confirming that any difference in outcomes observed between the two groups is attributable to the treatment. While randomized controlled trials (RCT) remain the gold standard in estimating ATE of therapeutic interventions, they do have inherent limitations due to uncertain external validity. Observational studies can have a complementary role in enhancing RCTs' ability to inform routine clinical practice. In this review, we focus on the limitations of observational studies, the need for randomization, interpretation, and the limitations of RCTs. © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022.

Entities:  

Keywords:  Average treatment effects; RCT; Randomization

Year:  2022        PMID: 36050978      PMCID: PMC9424468          DOI: 10.1007/s12055-022-01401-7

Source DB:  PubMed          Journal:  Indian J Thorac Cardiovasc Surg        ISSN: 0970-9134


  20 in total

1.  Bias and causal associations in observational research.

Authors:  David A Grimes; Kenneth F Schulz
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

Review 2.  Experimental Design, Randomization, and Validation.

Authors:  Keith Baggerly
Journal:  Clin Chem       Date:  2018-05-18       Impact factor: 8.327

Review 3.  Randomization: The forgotten component of the randomized clinical trial.

Authors:  William F Rosenberger; Diane Uschner; Yanying Wang
Journal:  Stat Med       Date:  2018-07-25       Impact factor: 2.373

4.  Spironolactone for heart failure with preserved ejection fraction.

Authors:  Bertram Pitt; Marc A Pfeffer; Susan F Assmann; Robin Boineau; Inder S Anand; Brian Claggett; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Brian Harty; John F Heitner; Christopher T Kenwood; Eldrin F Lewis; Eileen O'Meara; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Song Yang; Sonja M McKinlay
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

5.  Optimal medical therapy with or without PCI for stable coronary disease.

Authors:  William E Boden; Robert A O'Rourke; Koon K Teo; Pamela M Hartigan; David J Maron; William J Kostuk; Merril Knudtson; Marcin Dada; Paul Casperson; Crystal L Harris; Bernard R Chaitman; Leslee Shaw; Gilbert Gosselin; Shah Nawaz; Lawrence M Title; Gerald Gau; Alvin S Blaustein; David C Booth; Eric R Bates; John A Spertus; Daniel S Berman; G B John Mancini; William S Weintraub
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

6.  Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.

Authors:  Anne Christine H Ruwald; Bo Westergaard; Thomas Sehestedt; Sverre E Kjeldsen; Lars H Lindholm; Kristian Wachtell; Richard B Devereux; Hans Ibsen; Markku S Nieminen; Björn Dahlöf; Michael H Olsen
Journal:  J Hypertens       Date:  2012-06       Impact factor: 4.844

7.  Drug-eluting or bare-metal stents for acute myocardial infarction.

Authors:  Laura Mauri; Treacy S Silbaugh; Pallav Garg; Robert E Wolf; Katya Zelevinsky; Ann Lovett; Manu R Varma; Zheng Zhou; Sharon-Lise T Normand
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

8.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

Review 9.  Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction.

Authors:  Adnan Kastrati; Alban Dibra; Christian Spaulding; Gerrit J Laarman; Maurizio Menichelli; Marco Valgimigli; Emilio Di Lorenzo; Christoph Kaiser; Ilkka Tierala; Julinda Mehilli; Melchior Seyfarth; Olivier Varenne; Maurits T Dirksen; Gianfranco Percoco; Attilio Varricchio; Undine Pittl; Mikko Syvänne; Maarten J Suttorp; Roberto Violini; Albert Schömig
Journal:  Eur Heart J       Date:  2007-09-27       Impact factor: 29.983

10.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.